AXA Framlington Biotech
Ranked in Biotechnology 1/2 over 3 years
Total return 86.7% 3 years to 17/05/2013
Latest price £0.87 Updated 17/05/2013
Change in price 2.07% from 16/05/2013
Performance over 3 years
| Discrete yearly performance (%) for the 36 month period from Apr 10 to Apr 13 (month end to month end, bid/bid, gross income reinvested, calculated in £) | |||
| Apr 10 Apr 11 |
Apr 11 Apr 12 |
Apr 12 Apr 13 |
|
|---|---|---|---|
| AXA Framlington Biotech R Acc | |||
| 3.37% | 19.49% | 42.17% | |
| AMEX/Biotechnology CR | |||
| 11.92% | 3.56% | 36.71% | |
| NASDAQ Biotechnology TR | |||
| 9.19% | 20.06% | 44.49% | |
Related News
- Efficiency drive in US healthcare creates investment openings May 18, 2012 at 10:21
- The drugs do work! The return of pharma stocks Oct 30, 2008 at 09:47
Fund information
- Share ClassR Acc
- ISIN GB0031007254
Want more information? Email support@citywire.co.uk.